^
Association details:
| Biomarker: | HRD + BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/17/2023
Excerpt:
Recommendations...Maintenance treatment with PARPis, with or without bevacizumab, is recommended for patients with BRCA1/2-mutated or BRCA1/2-wt/HRD-positive tumors with no evidence of disease at the end of ChT or a complete or partial response to platinum–paclitaxel first-line ChT [I, A].
Source:
Published date:
08/17/2023
Excerpt:
Recommendations...Maintenance treatment with PARPis, with or without bevacizumab, is recommended for patients with BRCA1/2-mutated or BRCA1/2-wt/HRD-positive tumors with no evidence of disease at the end of ChT or a complete or partial response to platinum–paclitaxel first-line ChT [I, A].
Secondary therapy:
PARP inhibitors
